Table 3 Univariate and multivariate overall survival analysis in 3 HCC cohorts
| Â | Univariate Analysis | Multivariate Analysis | ||||
|---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | |
TCGA-LIHC Cohort I | ||||||
 Gender | ||||||
  Male vs. Female | 1.351 | 0.724–2.521 | 0.345 | 1.508 | 0.575–3.957 | 0.404 |
 Albumin (g/L) | ||||||
   > =35 vs. < 35 | 0.400 | 0.185–0.867 | 0.020 | 0.227 | 0.088–0.586 | 0.002 |
 AFP (ng/mL) | ||||||
   > =25 vs. < 25 | 2.437 | 1.019–5.827 | 0.045 | 2.972 | 1.100–8.030 | 0.032 |
 Tumor Stage | ||||||
  III/IV vs. I/II | 3.663 | 1.958–6.851 | 0.000 | 2.656 | 1.113–6.336 | 0.028 |
 Tumor Grade | ||||||
  G3/G4 vs. G1/G2 | 0.905 | 0.476–1.720 | 0.761 | 0.683 | 0.260–1.794 | 0.439 |
 Vascular Invasion | ||||||
  Yes vs. No | 1.512 | 0.720–3.177 | 0.275 | 0.927 | 0.335–2.563 | 0.884 |
 Sox Signature | ||||||
  High vs. Low | 4.045 | 2.174–7.525 | 0.000 | 1.272 | 0.397–4.075 | 0.686 |
TCGA-LIHC Cohort II | ||||||
 Gender | ||||||
  Male vs. Female | 1.142 | 0.744–1.753 | 0.542 | 1.255 | 0.659–2.389 | 0.490 |
 Albumin (g/L) | ||||||
   > =35 vs. < 35 | 1.109 | 0.643–1.912 | 0.710 | 1.107 | 0.553–2.217 | 0.774 |
 AFP (ng/mL) | ||||||
   > =25 vs. < 25 | 1.347 | 0.815–2.229 | 0.246 | 0.874 | 0.454–1.680 | 0.685 |
 Tumor Stage | ||||||
  III/IV vs. I/II | 1.914 | 1.203–3.048 | 0.006 | 1.826 | 1.117–2.984 | 0.016 |
 Tumor Grade | ||||||
  G3/G4 vs. G1/G2 | 1.198 | 0.776–1.849 | 0.415 | 1.336 | 0.900–1.982 | 0.150 |
 Vascular Invasion | ||||||
  Yes vs. No | 1.282 | 0.773–2.127 | 0.336 | 1.297 | 0.654–2.572 | 0.457 |
 Sox Signature | ||||||
  High vs. Low | 1.618 | 1.023–2.560 | 0.040 | 1.126 | 0.546–2.321 | 0.748 |
LIRI-JP Cohort | ||||||
 Gender | ||||||
  Male vs. Female | 1.926 | 1.033–3.590 | 0.039 | 2.507 | 1.315–4.779 | 0.005 |
 Tumor Stage | ||||||
  III/IV vs. I/II | 2.384 | 1.304–4.359 | 0.005 | 2.624 | 1.408–4.890 | 0.002 |
 Sox Signature | ||||||
  High vs. Low | 2.012 | 1.031–3.926 | 0.041 | 1.799 | 0.915–3.537 | 0.089 |